Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Mastroeni

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
American Journal of Clinical Pathology|June 14, 2014
High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanomaEster Alvino, Francesca Passarelli, Elda Cannavò, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 23, 2019
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-ASimona Caporali, Adriana Amaro, Lauretta Levati, et al.
Biomedicines|December 24, 2021
Reduced Interleukin-17-Expressing Cells in Cutaneous MelanomaAnna Tosi, Lavinia Nardinocchi, Maria Luigia Carbone, et al.
Scientific Reports|April 1, 2022
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patientsMaria Luigia Carbone, Gabriele Madonna, Alessia Capone, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2021
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patientsSofia Verkhovskaia, Francesca Romana Di Pietro, Simona Mastroeni, et al.
Cancers|April 14, 2026
Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell AnalysisAlessia Capone, Maria Luigia Carbone, Simona Mastroeni, et al.
Frontiers in Medicine|November 5, 2024
Implementing a group singing intervention for postpartum depression within the Italian health serviceIlaria Lega, Ilaria Luzi, Simona Mastroeni, et al.
Cancers|August 12, 2022
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted TherapyLauretta Levati, Cristian Bassi, Simona Mastroeni, et al.
Journal of Biomedical Science|February 26, 2026
TRKB-based signature identifies high-risk squamous cell carcinoma cases and TRKB blockade reprograms tumor and stromal cells toward suppressive phenotypesValeria Bartolocci, Alessio Capone, Rosanna Monetta, et al.
The British Journal of Dermatology|May 31, 2024
Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosaAlessia Primerano, Emanuela De Domenico, Francesca Cianfarani, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
American Journal of Clinical Pathology|June 14, 2014
High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanomaEster Alvino, Francesca Passarelli, Elda Cannavò, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 23, 2019
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-ASimona Caporali, Adriana Amaro, Lauretta Levati, et al.
Biomedicines|December 24, 2021
Reduced Interleukin-17-Expressing Cells in Cutaneous MelanomaAnna Tosi, Lavinia Nardinocchi, Maria Luigia Carbone, et al.
Scientific Reports|April 1, 2022
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patientsMaria Luigia Carbone, Gabriele Madonna, Alessia Capone, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2021
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patientsSofia Verkhovskaia, Francesca Romana Di Pietro, Simona Mastroeni, et al.
Cancers|April 14, 2026
Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell AnalysisAlessia Capone, Maria Luigia Carbone, Simona Mastroeni, et al.
Frontiers in Medicine|November 5, 2024
Implementing a group singing intervention for postpartum depression within the Italian health serviceIlaria Lega, Ilaria Luzi, Simona Mastroeni, et al.
Cancers|August 12, 2022
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted TherapyLauretta Levati, Cristian Bassi, Simona Mastroeni, et al.
Journal of Biomedical Science|February 26, 2026
TRKB-based signature identifies high-risk squamous cell carcinoma cases and TRKB blockade reprograms tumor and stromal cells toward suppressive phenotypesValeria Bartolocci, Alessio Capone, Rosanna Monetta, et al.
The British Journal of Dermatology|May 31, 2024
Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosaAlessia Primerano, Emanuela De Domenico, Francesca Cianfarani, et al.
Pageof 7